Abstract: Novel strains of the insecticidal microorganism Bacillus thurinaiensis are described. These contain novel genes, and in particular a gene coding for a novel insecticidal endotoxin, 81 kilodaltons in length, toxic to both Lepidoptera and Coleoptera. The novel strains and the genes they contain may be used to combat insect attack against plants.

Abstract: The invention provides a pharmaceutical composition comprising a particular physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methyl-benzenesulphonamide and polyvinylpyrrolidone. It also provides methods for preparing this physical form, and another physical form of N-[4-[5-(cyclopentyloxycarbonyl)amino-1-methylindol-3-yl-methyl]-3-methoxy benzoyl]-2-methylbenzenesulphonamide useful in the preparation of the first mentioned physical form. The compositions are useful in the treatment of diseases in which leukotrienes are implicated, for example asthma.

Abstract: A fuel tank cap structure which enables a cover member to be readily attached to a casing body. The fuel tank cap includes the casing body and the cover member that is rotatable in one direction relative to the casing body via a ratchet mechanism when a torque of or above a predetermined level is applied to the cover member. The cover member has fitting projections that are held by an outer ring member of the casing body. The outer ring member has a plurality of slits, which cause the outer ring member to be elastically deformed when riding over the fitting projections, thereby facilitating the engagement of the fitting projections with the outer ring member.

Abstract: A fuel tank cap structure and method of manufacturing which prevents a parting line formed on a cover member in the process of injection molding from being undesirably shaven. The fuel tank cap includes a casing body and a cover member that is rotatable in one direction relative to the casing body via a ratchet mechanism when a torque of or above a predetermined level is applied to the cover member. The cover member has fitting projections that are held by an outer ring member of the casing body. A slide mold is used for manufacturing the cover member having the fitting projections that are undercut in the injection molding. This causes a parting line to be formed on a top wall of the cover member. Anti-shaving projections formed at substantially the same height as that of the parting line prevent the parting line from being slid against the outer ring member and shaven.

Abstract: A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme capable of converting a prodrug into an antineoplastic drug, and a second component comprising a prodrug convertible under the influence of the mutated enzyme to the antineoplastic drug. The mutated enzyme is a mutated form of a natural host enzyme which recognizes its natural substrate by an ion pair interaction with the substrate, wherein the mutated enzyme and prodrug have structures such that the polarity of the mutated enzyme/prodrug ion pair interaction is reversed relative to the natural host enzyme/natural substrate ion pair interaction. The first component is substantially non-immunogenic in the host and the prodrug second component is not significantly convertible into antineoplastic drug in the host by natural unmutated host enzyme.

Abstract: A passive reservoir for medicament in the form of a plastics bag 1, has a hanging eyelet 2 at its upper end and a lower outlet nozzle 3. The plastics bag 1 has bottom corners 4,5, the left-hand right-angled corner 5 of which encapsulates a data carrier means 6 which carries data relating to a medicament contained or to be contained within the bag 1. The data carrier means is in the form of an electrically and/or magnetically operable device which can emit the data it is carrying in response to activation by a suitable field applied by an external reading device, which can cooperate with a delivery device to control the delivery to a patient of medicament when contained in the bag 1.

Abstract: A fuel cap structure which enables part of a flange member to be readily broken when an external force is applied via a cover member in any direction. A fuel cap includes a casing body and a cover member attached to the flange member formed on the upper portion of the casing body. The flange member includes a joint member to join the upper portion of the casing body with an outer ring member, in which the cover member is fitted. The joint member has fragile portions including notches. Each fragile portion starts a break of the joint member when an external force is applied to the flange member via the cover member in a variety of directions.

Abstract: The invention concerns compounds of formula (I), wherein each of G.sup.1, G.sup.2 and G.sup.6 is CH or n; m is 1 or 2; R.sup.1 includes hydrogen, halogeno and (1-4C)alkyl; M.sup.1 is a group of formula: NR.sup.2 -L.sup.1 -T.sup.1 R.sup.3, in which R.sup.2 and R.sup.3 together form a (1-4C)alkylene group, L.sup.1 includes (1-4C)alkylene, and T.sup.1 is CH or N; A may be a direct link; M.sup.2 is a group of the formula: (T.sup.2 R.sup.4).sub.r -L.sup.2 T.sup.3 R.sup.5 in which R is 0 or 1, each of T.sup.2 and T.sup.3 is CH or N, each of R.sup.4 and R.sup.5 is hydrogen or (1-4C)alkyl, or R.sup.4 and R.sup.5 together form a (1-4C)alkylene group, and L.sup.2 includes (1-4C)alkylene; M.sup.3 may be a direct link to X; X includes sulphonyl; and Q includes naphthyl and a heterocycle moiety; or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use as antithrombotic or anticoagulant agents.

Abstract: Compounds which inhibit prenyl transferases, particularly farnysyltransferase and geranylgeranyl transferase I, processes for preparing the compounds, pharmaceutical compositions containing the compounds, and methods of use.

Abstract: The invention concerns 4-anilinoquinazoline derivatives of the formula I ##STR1## wherein m is 1 or 2; each R.sup.1 includes hydrogen, halogeno, (1-4C)alkyl and (1-4C)alkoxy;n is 1, 2 or 3;each R.sup.2 includes hydrogen, hydroxy, halogeno and (1-4C)alkyl; and Ar is a 5- or 9-membered nitrogen-linked heteroaryl moiety containing up to four nitrogen heteroatoms, or Ar is a 5-, 6-, 9- or 10-membered nitrogen-linked unsaturated heterocyclic moiety containing up to three nitrogen heteroatoms which bears one or two substituents selected from oxo and thioxo such as 2-oxo-4-imidazolin-1-yl;or a pharmaceutically-acceptable salt thereof;processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.

Abstract: The invention concerns the quinazoline derivative 6-(2-methoxyethylamino)-7-methoxy-4-(3'-methylanilino)quinazoline, or a pharmaceutically-acceptable salt thereof, processes for its preparation, pharmaceutical compositions containing the compound and the use of the receptor tyrosine kinase inhibitory properties of the compound in the treatments of proliferative disease such as cancer.

Abstract: Yeast Artificial Chromosomes (YACS) containing DNA encoding the cystic fibrosis (CFTR) gene are described. The YACs allow detailed analysis of the coding and non-coding regions of the gene and the determination of cystic fibrosis alleles in sample DNA from an individual or individuals.

Abstract: The invention concerns quinazoline derivatives of formula wherein n is 1, 2 or 3 and each R.sup.2 is independently halogeno; and R.sup.1 is di-?(1-4C)alkyl!amino-(2-4C)alkoxy, pryolidin-1-yl-(2-4C)alkoxy,piperidino-(2-4C)alkoxy, morpholino-(2-4C)alkoxy, piperazin-1-yl-(2-4C)alkoxy or 4-(1-4C)alkylpiperazin-1-yl-(2-4C)alkoxy; or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.

Abstract: This invention relates to the measurement of various haemostatis, clotting, and the like properties of blood.

Abstract: An apparatus including: a sprayer for inoculating a microbe on a first division divided from at least one sample of a plant to be examined; sample leaving device for leaving a second division divided from the sample not inoculated with the microbe and the first division inoculated with the microbe, for a predetermined period of time under a predetermined condition; first and second photodetector for respectively measuring the quantities of luminescence emitted from the first and second divisions which have been left standing by the sample leaving device; and a computer for comparing the quantities of the luminescence measured by the first and second photodetector, thereby to examine the resistance or susceptibility of the plant to the microbe.

Abstract: Compounds of formula (I) wherein R.sup.1 is hydrogen or hydroxy; R.sup.2 is hydrogen; or R.sup.1 and R.sup.2 are joined together so that CR.sup.1 14 CR.sup.2 is a double bond; X is selected from --Ch.sub.2 CH.sub.2 --, --C.dbd.CH--, --C.tbd.C--, --CH.sub.2 O--, --OCH.sub.2, CH.sub.2 NH--, --NHCH.sub.2 --, --CH.sub.2 CO--, --COCH.sub.2 --, --CH.sub.2 S(O).sub.n -- and --S(O).sub.n CH.sub.

Abstract: Method of preparing an optically active compound of formula, wherein R and R.sup.1 are independently alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, cycloalkyl, aryl, aralkyl, a heterocyclic group or a C.sub.1 -C.sub.4 alkyl-heterocycle, each being optionally substituted, procided that R and R.sup.1 are not identical and * is an optically active chiral center, from the corresponding racemic ester or diol by treating with a hydrolase enzyme.

Abstract: Pharmaceutical compositions containing 2,6-diisopropylphenol (propofol) are described for use as anaesthetics. A method for their preparation is described, as their use in producing anaesthesia including induction and maintenance of general anaesthesia and sedation.

Abstract: The invention relates to a tank with an inner and/or outer cladding or lining, consisting of a tank wall and a double-walled cladding adhering to the latter and consisting of a double pile fabric which is reinforced by a curable impregnated resin and in which an upper and a lower fabric are connected so as to be spaced from one another by means of webs formed by pile threads, and with a closing-off laminate ply, the webs of the cladding forming, between the upper and the lower fabric, web walls extending linearly in one direction and consisting in each case of a multiplicity of pile threads arranged next to one another, and the web walls extending parallel to one another with small web heights of about 2.5 to 3.5 mm and with web wall spacings, greater than these of about 5 to 8 mm and, together with the upper and the lower fabric, delimiting individual cavity ducts.

Abstract: A (substituted-aralkyl)heterocyclic compound of the formula I ##STR1## wherein R.sup.1 is an azido, carbamoyl, cyano, formyl, hydroxy or nitro radical, a 1-6C 1-hydroxyalkyl, alkoxy, alkylcarbamoyl, alkylthio, alkylsulphinyl or alkylsulphonyl radical, a 2-cyanoethyl radical, optionally bearing one to four 1-6C alkyl substituents, or a 2-6C alkanoyl, halogenoalkanoyl, alkanoyloxy, alkanoylamino, dialkylcarbamoyl or alkoxycarbonyl radical; R.sup.2 and R.sup.3, which may be the same or different, are each a hydrogen atom, a 1-6C alkyl, dueterioalkyl or halogenoalkyl radical, or a phenyl or phenyl(1-6C alkyl) radical, in each of which the phenyl may optionally bear one or more substituents; or R.sup.2 and R.sup.3, together with the carbon atom to which they are attached, may form a 3- to 6-membered ring; or R.sup.1 R.sup.2 R.sup.3 C- is a 1,1-dicyanoethyl or trifluoromethylsulphonyl radical; R.sup.4 is a hydrogen or halogen atom, a cyano or nitro radical or a 1-6C alkyl or halogenoalkyl radical; R.sup.